The	0	3	O
merits	4	10	O
of	11	13	O
vascular	14	22	O
targeting	23	32	O
for	33	36	O
gynecologic	37	48	O
malignancies	49	61	O
.	61	62	O

Neovascularization	64	82	O
is	83	85	O
an	86	88	O
early	89	94	O
and	95	98	O
critical	99	107	O
step	108	112	O
in	113	115	O
tumor	116	121	B-Pathological_formation
development	122	133	O
and	134	137	O
progression	138	149	O
.	149	150	O

Tumor	151	156	B-Multi-tissue_structure
vessels	157	164	I-Multi-tissue_structure
are	165	168	O
distinct	169	177	O
from	178	182	O
their	183	188	O
normal	189	195	O
counterparts	196	208	O
morphologically	209	224	O
as	225	227	O
well	228	232	O
as	233	235	O
at	236	238	O
a	239	240	O
molecular	241	250	O
level	251	256	O
.	256	257	O

Recent	258	264	O
studies	265	272	O
on	273	275	O
factors	276	283	O
involved	284	292	O
in	293	295	O
tumor	296	301	B-Multi-tissue_structure
vascular	302	310	I-Multi-tissue_structure
development	311	322	O
have	323	327	O
identified	328	338	O
new	339	342	O
therapeutic	343	354	O
targets	355	362	O
for	363	366	O
inhibiting	367	377	O
tumor	378	383	B-Pathological_formation
neovascularization	384	402	O
and	403	406	O
thus	407	411	O
tumor	412	417	B-Pathological_formation
progression	418	429	O
.	429	430	O

However	431	438	O
,	438	439	O
the	440	443	O
process	444	451	O
of	452	454	O
tumor	455	460	B-Multi-tissue_structure
blood	461	466	I-Multi-tissue_structure
vessel	467	473	I-Multi-tissue_structure
formation	474	483	O
is	484	486	O
complex	487	494	O
,	494	495	O
and	496	499	O
each	500	504	O
tumor	505	510	B-Pathological_formation
exhibits	511	519	O
unique	520	526	O
features	527	535	O
in	536	538	O
its	539	542	O
vasculature	543	554	B-Multi-tissue_structure
.	554	555	O

An	556	558	O
understanding	559	572	O
of	573	575	O
the	576	579	O
relative	580	588	O
contribution	589	601	O
of	602	604	O
various	605	612	O
pathways	613	621	O
in	622	624	O
the	625	628	O
development	629	640	O
of	641	643	O
tumor	644	649	B-Multi-tissue_structure
vasculature	650	661	I-Multi-tissue_structure
is	662	664	O
critical	665	673	O
for	674	677	O
developing	678	688	O
effective	689	698	O
and	699	702	O
selective	703	712	O
therapeutic	713	724	O
approaches	725	735	O
.	735	736	O

Several	737	744	O
such	745	749	O
agents	750	756	O
are	757	760	O
currently	761	770	O
in	771	773	O
clinical	774	782	O
trials	783	789	O
,	789	790	O
and	791	794	O
many	795	799	O
others	800	806	O
are	807	810	O
under	811	816	O
development	817	828	O
.	828	829	O

In	830	832	O
this	833	837	O
review	838	844	O
,	844	845	O
the	846	849	O
mechanisms	850	860	O
and	861	864	O
factors	865	872	O
involved	873	881	O
in	882	884	O
tumor	885	890	B-Multi-tissue_structure
blood	891	896	I-Multi-tissue_structure
vessel	897	903	I-Multi-tissue_structure
formation	904	913	O
are	914	917	O
discussed	918	927	O
.	927	928	O

In	929	931	O
addition	932	940	O
,	940	941	O
selected	942	950	O
novel	951	956	O
classes	957	964	O
of	965	967	O
antivascular	968	980	O
therapies	981	990	O
,	990	991	O
including	992	1001	O
those	1002	1007	O
targeting	1008	1017	O
tumor	1018	1023	B-Cell
endothelial	1024	1035	I-Cell
cells	1036	1041	I-Cell
and	1042	1045	O
other	1046	1051	O
components	1052	1062	O
of	1063	1065	O
the	1066	1069	O
tumor	1070	1075	B-Multi-tissue_structure
vasculature	1076	1087	I-Multi-tissue_structure
,	1087	1088	O
are	1089	1092	O
summarized	1093	1103	O
.	1103	1104	O

